Loratadine Market – By Dosage Form (Tablets, Capsules, Syrups), Route of Administration (Oral, Topical), Type (Branded, Generis), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 – 2032)

Loratadine Market Size

Loratadine Market size was valued at USD 140.1 million in 2023 and is anticipated to grow at a CAGR of 2.8% between 2024 – 2032. One of the major growth drivers is the increasing prevalence of allergic rhinitis and other allergic disorders globally.
 

For instance, as per a study published in 2022, allergic rhinitis (AR) represents a global health concern where it affects approximately 400 million people worldwide. Loratadine, known for its effectiveness in relieving symptoms such as sneezing, itching, and runny nose, is widely prescribed to manage these conditions, thereby fueling market growth. Additionally, the growing awareness among patients regarding the OTC availability and benefits of allergic rhinitis drugs, such as loratadine is contributing to its market expansion. Moreover, the availability of loratadine in various forms such as tablets, syrups, and dissolvable tablets, providing convenience to patients of different age groups, further propels market growth.
 

Loratadine is a second-generation antihistamine drug commonly used to treat allergic rhinitis (hay fever), as well as symptoms of urticaria (hives) such as itching, redness, and swelling. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. Loratadine is available in various forms, including tablets, syrup, and capsules. It is often preferred for its non-drowsy formulation, making it suitable for daytime use.
 

Loratadine Market Trends

• Increasing prevalence of allergic conditions, including allergic rhinitis, hay fever, and hives is a significant driver of the market.
   
• For instance, according to the National Center for Health Statistics, the prevalence of diagnosed allergic conditions in adults in the U.S. in 2021 was 28.2%, with allergic rhinitis being one of the conditions included in this category. Similarly, a study published in 2023 by the National Institute of Health (NHI), reported that the global prevalence of allergic rhinitis was 20% in 2018, but it is estimated to have been 10 to 15% in 2021.
   
• Loratadine, a second-generation antihistamine, is commonly used to relieve symptoms associated with these allergic reactions. Thus, as allergies become more common globally, driven by factors such as environmental changes, pollution, and genetic predispositions, the demand for effective allergy therapeutics like loratadine continues to rise.
   
• Further, easy availability of loratadine as over the counter (OTC) drug has greatly contributed to its market growth. The OTC availability allows consumers easier access to the medication without the need for a doctor's prescription, leading to increased sales and usage. This accessibility has made loratadine a preferred choice for many individuals seeking relief from allergies, further boosting its market demand and expansion.
   

Loratadine Market Analysis

Based on dosage form, the market is segmented into tablets, capsules, syrups, and other dosage forms. The tablets segment dominated the market is 2023 and accounted for USD 63.5 million.
 

• Tablets are a popular dosage form among consumers due to their convenience, ease of administration, and familiarity. Additionally, these offer advantages in terms of manufacturing efficiency and stability, making them a cost-effective choice for both manufacturers and consumers.
   
• Further, tablets can be easily formulated with different release profiles, allowing for extended-release or fast-acting formulations to meet diverse patient needs.
   
• Moreover, high effectiveness, versatility, and widespread acceptance among patients and healthcare providers, further drivers the market share of tablets in market.
   

Based on route of administration, the loratadine market is segmented into oral and topical. The oral segment dominated the market with 87% of market share in 2023.
 

• The oral form is favored by patients due to its convenience, ease of administration, and rapid onset of action. Additionally, availability of loratadine in various types of oral formulations, such as tablets, chewable tablets, and syrups, further increases its adoption rates.
   
• In addition, the oral segment's dominance is also driven by the widespread availability of generic versions, making it a cost-effective option for both consumers and healthcare providers.

Based on type, the loratadine market is categorized into branded and generic. The branded segment dominated the market and is predicted to grow at CAGR of 2.6% over the forecast period.
 

• Brand recognition plays a significant role, as consumers often trust established brands for their quality and effectiveness. Additionally, marketing strategies such as extensive advertising campaigns and promotional activities contribute to increased brand visibility and consumer loyalty.
   
• Furthermore, partnerships with healthcare providers and endorsements from medical professional’s influence consumer trust and preference for branded loratadine products. Also, brand reputation for safety and efficacy plays a role in consumer choice, thereby enhancing the segmental growth.
   

Based on distribution channel, the loratadine market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held highest market share in 2023 and is anticipated to reach USD 106.7 million by 2032.
 

• Hospitals are key dispensers of medications, including loratadine, often providing this antihistamine to patients for allergic conditions. Thus, hospital pharmacies benefit from large patient pool in hospitals for primary care.
   
• Additionally, hospital pharmacies benefit from bulk purchasing and distribution efficiencies, allowing them to procure loratadine at competitive prices.
   
• Further, convenience of obtaining loratadine directly from the hospital where patients receive treatment also contributes to the segment's high market share.

North America loratadine market is anticipated to grow at a CAGR of 2.6% over the forecast years to reach USD 62.0 million by 2032.
 

• One of the primary drivers is the high prevalence of allergies in the region, which has led to a substantial demand for effective antihistamines like loratadine. Additionally, the well-established healthcare infrastructure and high awareness about allergy management contribute to the widespread use of loratadine.
   
• Moreover, the presence of prominent pharmaceutical companies focusing on allergy medications further bolsters the market in North America.
   

U.S. loratadine market was valued at USD 43.9 million in 2023.
 

• Loratadine is widely available over the counter in the U.S., contributing to its accessibility and widespread use.
   
• Additionally, high prevalence rates of allergic conditions in the country such as hay fever and allergic rhinitis, further boosts demand for loratadine. For instance, the prevalence of allergic rhinitis in the U.S. is approximately 15% based on physician diagnoses and as high as 30% based on self-reported nasal symptoms.
   
• Further, extensive marketing efforts by pharmaceutical companies promoting loratadine-based products have helped maintain its strong market presence in the country.
   

UK has emerged as a key player in the global market for loratadine, showcasing high growth potential.
 

• UK's growing aging population, coupled with changing climate patterns leading to longer pollen seasons, boosts the need for effective allergy relief medications like loratadine.
   
• Additionally, the trend towards self-medication and over the counter (OTC) purchases of such drugs is on the rise in the UK, contributing to the market's growth.
   
• Moreover, the country's well-established healthcare infrastructure, coupled with robust regulatory frameworks ensuring safe and effective drug use, further support the expansion of the market in the UK.
   

India loratadine market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The increasing prevalence of allergic rhinitis and other allergic conditions is driving the demand for loratadine.
   
• For instance, an Indian study reported that prevalence of allergic rhinitis was 11·3% in children aged 6–7 years, and 24·4% in children aged 13–14 years.
   
• Additionally, the country's large population, combined with rising disposable incomes and increased awareness of health issues, is fueling the growth of the pharmaceutical market, including antihistamines like loratadine.
   

Loratadine Market Share

The loratadine industry is fragmented in nature characterized by the presence of several pharmaceutical companies. The key market players are focused on developing improved treatments, such as longer-acting formulations and combination therapies to develop and launch new products in the market. These players are constantly engaged in growth strategies such as partnerships and collaborations, and new product launches to enhance their product portfolio.
 

Loratadine Market Companies

Prominent players operating in the loratadine industry include:

• Bayer AG
• Cadila Pharmaceuticals Limited
• Cipla Ltd.
• Lannett Company, Inc.
• Merck KGaA
• Morepen Laboratories Ltd
• Perrigo Company plc
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Viatris Inc.
   

Loratadine Industry News:

• In January 2021, JB Chemicals & Pharmaceuticals received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for loratadine tablets USP 10 mg for over the counter (OTC) use. This approval is significant as it marked a milestone for JB Chemicals & Pharmaceuticals in the U.S. market.
   
• In December 2019, Granules India received U.S. Food & Drug Administration approval for the Abbreviated New Drug Application (ANDA) filed for loratadine tablets USP, 10 mg (OTC). This helped the company expand its product offerings in the U.S. market and increase sales.
   

The loratadine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Dosage Form

• Tablets
• Capsules
• Syrups
• Other dosage forms

Market, By Route of Administration

• Oral
• Topical

Market, By Type

• Branded
• Generic

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa